Why Trump Is Pushing Psychedelics To Treat Mental Illness
The Trump administration signed an executive order on April 18th to fast-track FDA review of psychedelic drugs for mental health treatment, issuing priority vouchers to three companies. While veterans and advocates praise the potential of treatments like MDMA and psilocybin for PTSD and depression, scientists warn that rushing the approval process could compromise research rigor. The move marks a sharp reversal from Trump's first-term drug stance, with some suggesting it may be politically motivated.
Summary
On April 18th, the Trump administration signed an executive order aimed at accelerating FDA review of psychedelic drugs for treating serious mental illnesses, particularly for patients who have not responded to traditional therapies. Three drug companies received priority review vouchers, including Compass Pathways — the only public company among them — whose stock rallied alongside the broader psychedelic drug sector following the announcement. The order also included the reclassification of marijuana and highlighted medical benefits of alternative medicines, representing a significant policy reversal from Trump's first term.
The executive order specifically named psilocybin, MDMA, LSD, and ibogaine as compounds of interest. Psilocybin has the most robust clinical evidence, with published Phase 2 and early Phase 3 data from Usona Institute and Compass Pathways showing promise for major depressive disorder. MDMA, technically classified as an empathogen rather than a classic psychedelic, has shown strong results in PTSD treatment — one study found over 70% of severe PTSD participants no longer met diagnostic criteria after MDMA-assisted therapy — yet the FDA rejected an application for it in 2024 due to concerns about study design. Ibogaine, meanwhile, has never undergone a U.S. clinical trial and carries known cardiovascular risks, making its inclusion in the executive order controversial among scientists.
Veterans featured in the segment provided personal testimony about the transformative impact of psychedelic-assisted therapy. Marie Phelan, an Army Reserve veteran diagnosed with complex PTSD in 2023, described her MDMA-assisted therapy experience in a VA clinical trial as allowing her to emotionally process years of trauma. Juliana Mercer, a Marine Corps veteran and executive director of Healing Breakthrough, spoke about how her psychedelic experience gave her 'permission to heal' and emphasized the importance of preparing the VA for real-world clinical implementation.
Scientists and researchers expressed concern that the executive order's accelerated timeline — compressing the FDA review from the standard ~10 months to roughly 1-2 months — could lead to approval based on insufficient data or politically motivated relaxation of standards. They stressed the need for rigorous, objective evaluation of both safety and efficacy, particularly given the varying risk profiles of different compounds. Despite these concerns, proponents like Compass Pathways argue that companies already in late-stage trials are being held to the same FDA standards as any other drug.
The political context of the executive order was also scrutinized. With Trump's economic approval ratings at their lowest point across both terms, some industry sources suggested the move may be an attempt to win back supporters, particularly veterans. However, veterans interviewed were skeptical of this framing, noting that cuts to VA funding and veteran benefits undermined any goodwill generated by the executive order. Advocates like Mercer insisted their vocal support was self-motivated and not politically coerced.
Key Insights
- Scientists argue that ibogaine's inclusion in the executive order overstates the current level of scientific understanding, noting there has never been a U.S. clinical trial examining its safety or efficacy, while it also carries known cardiovascular risks.
- The FDA ultimately rejected MDMA-assisted therapy in 2024 despite one study showing over 70% of severe PTSD participants no longer met diagnostic criteria, citing concerns about the quality and rigor of the underlying research.
- Compass Pathways notes that its drugs were already in the final phase of clinical trials and would have been submitted to the FDA this year regardless, meaning the executive order's expedited timeline primarily benefits companies further back in the pipeline.
- A researcher expresses concern that FDA standards could be relaxed for politically motivated reasons, stressing the need for objective scientific evaluation that includes perspectives such as cardiologists' assessments of compound-specific harms.
- Veterans interviewed are skeptical that the executive order will win back political support, with one veteran noting that cuts to VA funding and benefits undermine any goodwill, saying 'you're not even going to get my support if you fully fund the VA and benefits.'
Topics
Transcript
[0:00] Some psychedelic drugs in the United States are the closest they've ever been to getting FDA approval. In late April, three drug companies were issued priority vouchers by the FDA. The goal fast track the final stages of their review. It was part of an executive order signed by the Trump administration on April 18th, which notes that psychedelics have shown potential in clinical studies to address serious mental illnesses for patients who have already tried traditional treatment options. It certainly gives a significant tailwind encouragement, validation, but it's really to a lot of [0:31] work that was already underway, particularly for companies like ourselves. Compass Pathways is the only public company to receive one of the priority vouchers,…
Full transcript available for MurmurCast members
Sign Up to AccessMore from CNBC
Watch AI Dock A Boat
CNBC's Contessa Brewer demonstrates a 36-foot Cray boat equipped with advanced marine technology, including GPS, radar, and newly launched autonomous docking capabilities. The boat's base price is $550,000, with fully equipped models featuring autopilot and autonomous docking reaching $880,000.
What Will TV Look Like In 3 Years?
Industry leaders predict that TV will continue its shift toward streaming and live content over the next three years, with cable subscribers declining further and AI enabling personalized, multilingual viewing experiences. Sports remain a critical driver of viewership as one of the few irreplaceable live experiences, while new aggregator services and platforms like Tubi and Roku Channel are expected to gain significant market share.
To keep growing, Best Buy wants to go smaller
Best Buy is launching small and medium-format stores this summer as part of a strategic pivot following years of declining sales and stock performance post-COVID. New CEO Jason Bonfig will take over from Corie Barry in October and plans to accelerate growth through this revised store strategy while capitalizing on the AI boom.
How Audi hopes to win back consumers
Audi is attempting to regain market competitiveness by launching three new premium SUVs, including the Q9 and SQ9, featuring advanced technologies like smart headlights and OLED lighting. The brand has struggled since 2020, falling behind BMW and Mercedes-Benz in quality rankings and market share, with recent losses attributed to tariffs and the end of federal EV subsidies.
Inside SK Hynix: We Went To Korea To See The World's Biggest AI Memory Buildout
SK Hynix, South Korea's memory chip giant, is undertaking a historic $720 billion expansion to triple HBM (high-bandwidth memory) capacity by 2034, driven by unprecedented AI demand. The company is building massive new facilities in Korea while establishing its first U.S. packaging fab in Indiana, though it faces traditional boom-bust cycle risks and competition from Samsung, Micron, and Chinese manufacturers.